Triple-acting insulin reduces blood sugar and weight

A new clinical trial results for the drug "Retatrotide" for the treatment of type 2 diabetes have emerged, showing a reduction in blood sugar levels by up to 1.9 percentage points and weight loss between 11.5% and 15.3% after 40 weeks, compared to the control group. The medication works by mimicking three major intestinal hormones and stands out from traditional treatments due to its effectiveness in regulating appetite and reducing patient weight. These results indicate a significant advancement in diabetes treatment options, although further long-term studies are still needed.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل